AMLX - SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi LLP Investigates Claims on Behalf of Investors of Amylyx | Benzinga
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") (NASDAQ:AMLX) and reminds investors of the April 9, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $100,000 investing in Amylyx stock or options between November 11, 2022 and November 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/AMLX.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Defendants had overstated RELYVRIO's ...